Enzymatica AB Stock

Equities

ENZY

SE0003943620

Pharmaceuticals

Delayed Nasdaq Stockholm 11:00:43 2024-04-29 EDT 5-day change 1st Jan Change
2.89 SEK -6.17% Intraday chart for Enzymatica AB -16.23% -26.74%

Financials

Sales 2024 * 6.04M 66.04M 8.25M Sales 2025 * 11.85M 129M 16.17M Capitalization 48.71M 532M 66.49M
Net income 2024 * -5M -54.64M -6.83M Net income 2025 * -1M -10.93M -1.37M EV / Sales 2024 * 8.59 x
Net Debt 2024 * 3.18M 34.79M 4.35M Net cash position 2025 * 2.05M 22.43M 2.8M EV / Sales 2025 * 3.94 x
P/E ratio 2024 *
-16.5 x
P/E ratio 2025 *
-35.1 x
Employees 18
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-6.17%
1 week-16.23%
Current month-11.08%
1 month-11.89%
3 months-17.66%
6 months-22.83%
Current year-26.74%
More quotes
1 week
2.81
Extreme 2.81
3.59
1 month
2.81
Extreme 2.81
3.94
Current year
2.31
Extreme 2.305
4.10
1 year
2.10
Extreme 2.1
4.43
3 years
2.10
Extreme 2.1
13.40
5 years
1.88
Extreme 1.88
24.70
10 years
1.82
Extreme 1.815
24.70
More quotes
Managers TitleAgeSince
Founder 59 06-12-31
Chief Executive Officer 63 17-07-17
Director of Finance/CFO 55 17-12-31
Members of the board TitleAgeSince
Chairman 62 16-12-18
Director/Board Member 56 16-02-14
Director/Board Member 57 21-04-30
More insiders
Date Price Change Volume
24-04-29 2.89 -6.17% 220 683
24-04-26 3.08 -4.94% 173,251
24-04-25 3.24 -8.22% 96,511
24-04-24 3.53 +2.62% 12,555
24-04-23 3.44 -0.29% 23,983

Delayed Quote Nasdaq Stockholm, April 29, 2024 at 11:00 am

More quotes
Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Quarterly revenue - Rate of surprise